These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 30641300)

  • 1. Adherence to adjuvant endocrine therapy in postmenopausal breast cancer patients: A 5-year prospective study.
    Hagen KB; Aas T; Kvaløy JT; Søiland H; Lind R
    Breast; 2019 Apr; 44():52-58. PubMed ID: 30641300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer.
    Ejlertsen B; Jensen MB; Mouridsen HT;
    Acta Oncol; 2014 Feb; 53(2):174-85. PubMed ID: 24219541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to Adjuvant Endocrine Therapy in Women With Breast Cancer: A Prospective Observational Study in Japanese Women.
    Kuba S; Maeda S; Matsumoto M; Yamanouchi K; Yano H; Morita M; Sakimura C; Hatachi T; Tokai Y; Takatsuki M; Fujioka H; Hayashida N; Nagayasu T; Eguchi S
    Clin Breast Cancer; 2018 Apr; 18(2):150-156. PubMed ID: 29290564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
    Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Linn SC
    Eur J Cancer; 2018 Feb; 90():92-101. PubMed ID: 29274928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.
    Ziller V; Kalder M; Albert US; Holzhauer W; Ziller M; Wagner U; Hadji P
    Ann Oncol; 2009 Mar; 20(3):431-6. PubMed ID: 19150950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
    Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada.
    Blanchette PS; Lam M; Richard L; Allen B; Shariff SZ; Vandenberg T; Pritchard KI; Chan KKW; Louie AV; Desautels D; Raphael J; Earle CC
    Breast Cancer Res Treat; 2020 Jan; 179(1):217-227. PubMed ID: 31571072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
    Winer EP; Hudis C; Burstein HJ; Wolff AC; Pritchard KI; Ingle JN; Chlebowski RT; Gelber R; Edge SB; Gralow J; Cobleigh MA; Mamounas EP; Goldstein LJ; Whelan TJ; Powles TJ; Bryant J; Perkins C; Perotti J; Braun S; Langer AS; Browman GP; Somerfield MR
    J Clin Oncol; 2005 Jan; 23(3):619-29. PubMed ID: 15545664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study.
    Frechette D; Paquet L; Verma S; Clemons M; Wheatley-Price P; Gertler SZ; Song X; Graham N; Dent S
    Breast Cancer Res Treat; 2013 Aug; 141(1):111-7. PubMed ID: 23942873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported Adherence to Adjuvant Aromatase Inhibitor Therapy Using the Morisky Medication Adherence Scale: An Evaluation of Predictors.
    Kesmodel SB; Goloubeva OG; Rosenblatt PY; Heiss B; Bellavance EC; Chumsri S; Bao T; Thompson J; Nightingale G; Tait NS; Nichols EM; Feigenberg SJ; Tkaczuk KH
    Am J Clin Oncol; 2018 May; 41(5):508-512. PubMed ID: 27322700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients.
    He W; Smedby KE; Fang F; Olsson H; Margolin S; Hall P; Czene K
    J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28423398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-related differences in persistence in women with breast cancer treated with tamoxifen or aromatase inhibitors in Germany.
    Jacob L; Hadji P; Kostev K
    J Geriatr Oncol; 2016 May; 7(3):169-75. PubMed ID: 27091510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.
    Kimmick G; Edmond SN; Bosworth HB; Peppercorn J; Marcom PK; Blackwell K; Keefe FJ; Shelby RA
    Breast; 2015 Oct; 24(5):630-6. PubMed ID: 26189978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obesity and endocrine therapy: host factors and breast cancer outcome.
    Goodwin PJ
    Breast; 2013 Aug; 22 Suppl 2():S44-7. PubMed ID: 24074791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.
    Hershman DL; Kushi LH; Shao T; Buono D; Kershenbaum A; Tsai WY; Fehrenbacher L; Gomez SL; Miles S; Neugut AI
    J Clin Oncol; 2010 Sep; 28(27):4120-8. PubMed ID: 20585090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant endocrine therapy for postmenopausal women: Type and duration.
    Mayer EL; Burstein HJ
    Breast; 2015 Nov; 24 Suppl 2():S126-8. PubMed ID: 26279133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study.
    Harborg S; Heide-Jørgensen U; Ahern TP; Ewertz M; Cronin-Fenton D; Borgquist S
    Breast Cancer Res Treat; 2020 Aug; 183(1):153-160. PubMed ID: 32572715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.